Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q4 2015 (← Previous) (Next →)

Filing Date: May 5, 2016

Total Value ($000): $170,904,743 (100.0% shares, 0.0% debt)

Holdings (7)

GKOS Glaukos Corporation 45.4%

Value ($000) $77,581,337 Shares 3,136,232 Est. Cost $30.09 Unrealized -23.7%

— Five Prime Therapeutics, Inc. 26.5%

Value ($000) $45,324,308 Shares 1,092,152 Est. Cost $27000.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 12.1%

Value ($000) $20,758,148 Shares 2,215,384 Est. Cost $20.09 Unrealized -46.3%

— Clovis Oncology, Inc. 8.3%

Value ($000) $14,259,560 Shares 407,416 Est. Cost $56000.00 Unrealized —

— Achaogen, Inc. 4.3%

Value ($000) $7,353,812 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— Biotie Therapies Corp. 2.3%

Value ($000) $3,855,443 Shares 268,672 Est. Cost $19970.00 Unrealized —

— CymaBay Therapeutics, Inc. 1.0%

Value ($000) $1,772,135 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
GKOS	Glaukos Corporation	3,136,232	$77,581,337	45.4%	$30.09	-23.7%	Common Stock	377322102
—	Five Prime Therapeutics, Inc.	1,092,152	$45,324,308	26.5%	$27000.00	—	Common Stock	33830X104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$20,758,148	12.1%	$20.09	-46.3%	Common Stock	67576A100
—	Clovis Oncology, Inc.	407,416	$14,259,560	8.3%	$56000.00	—	Common Stock	189464100
—	Achaogen, Inc.	1,281,152	$7,353,812	4.3%	$13050.00	—	Common Stock	004449104
—	Biotie Therapies Corp.	268,672	$3,855,443	2.3%	$19970.00	—	ADS	09074D103
—	CymaBay Therapeutics, Inc.	1,048,601	$1,772,135	1.0%	$9830.00	—	Common Stock	23257D103